A Modified GLP-1 Peptide That Resists Breakdown Shows Metabolic Benefits in Obese Mice

Researchers used solid-phase peptide synthesis to create GLP-1 analogues with aza-substitutions (replacing α-carbon with nitrogen) at protease-sensitive residues. They evaluated DPP-4 resistance in vitro, measured GLP-1 receptor signaling potency, and assessed plasma half-life in mice. In vivo efficacy was tested in lean mice (oral glucose tolerance) and in high-fat diet-induced obese mice (chronic administration measuring body weight, glucose handling, insulin, leptin, and inflammatory markers).

Current GLP-1 drugs like semaglutide and liraglutide use various strategies to extend their half-life, but they still require modifications like fatty acid chains or PEGylation. Azapeptide substitution represents an entirely different approach — modifying the peptide backbone itself to resist enzymatic breakdown while preserving biological activity. If this translates to humans, it could lead to a new class of longer-lasting, potentially simpler GLP-1 therapies for diabetes and obesity.

The global race to improve GLP-1-based therapies is intense. While current drugs already work well, they rely on complex modifications to extend half-life. Azapeptide technology offers an elegant alternative — a minimal chemical change that fundamentally alters proteolytic vulnerability. This proof-of-concept could extend beyond GLP-1 to any therapeutic peptide limited by rapid degradation, potentially transforming the broader peptide drug development landscape.

This is a preprint (bioRxiv) that has not yet undergone peer review. All experiments were conducted in mice, and translation to humans is uncertain. Specific dosing details and exact weight loss percentages were not provided in the abstract. Long-term safety and efficacy data beyond the chronic dosing period are unavailable. The comparison was against unmodified GLP-1, not against approved drugs like semaglutide.